Opexa announces plans for at-the-market deal to sell 1 million shares

Agent IFS Securities conducts offering, will be paid a 3% commission

By Devika Patel

Knoxville, Tenn., March 28 – Opexa Therapeutics, Inc. arranged an at-the-market sales agreement with IFS Securities, Inc. on March 25, according to an 8-K and prospectus supplement filed Friday with the Securities and Exchange Commission. The agreement to sell up to 1 million common shares replaces a terminated sales agreement that was arranged on Sept. 6, 2012 with Meyers Associates, LP.

IFS will be paid a 3% commission.

Proceeds will be used for clinical studies and general corporate purposes, including working capital, research and development, business development and operational purposes.

Based in the Woodlands, Texas, the biopharmaceutical company develops personalized immunotherapies for autoimmune disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.